Lesabelimab is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Lesabelimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Monoclonal antibody is under development for the treatment of advanced malignant tumors including invasive bladder cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma and penile squamous cell carcinoma, endometrial cancer, cervical cancer, ovarian cancer, colorectal cancer, advanced non-clear cell renal cancer and advanced penile cancer and unspecified indication. It acts by targeting PD L1. The drug candidate is administered as injection.
Dragonboat Biopharmaceutical (Shanghai) overview
Dragonboat Biopharmaceutical (Shanghai) (Dragonboat Biopharmaceutical) is the research and development laboratory of Dragonfly Sciences, the US. It discovers and develops antibody therapeutics. Its platforms includes Analysis and Evaluation Platform, Process Development Platform, GMP Manufacturing Platform, Discovery platform, Quality Management Platform and Regulatory Affairs Platform. It discovers, develops, and commercializes genetically engineered human proteins for therapeutic use. Based on its proprietary protein expression technology, the company produces Erythropoietin, a drug that treats severe anemia. Dragonboat Biopharmaceutical is headquartered in Shanghai, China.
For a complete picture of Lesabelimab’s drug-specific PTSR and LoA scores, buy the report here.